Hair loss sits at the center of this dementia and brain health question.

The side effect men are never warned about when they take finasteride for hair loss is not sexual dysfunction, though that gets the most attention. It is depression, and in severe cases, suicidal ideation. A study of former finasteride users who developed persistent sexual side effects found that 75% had depressive symptoms, compared to just 10% in a control group. Suicidal thoughts were present in 44% of those former users, versus 3% of controls. These are not rare edge cases buried in medical literature. They are patterns that regulatory agencies have spent years catching up to, and that many prescribing doctors still do not mention during a routine consultation about thinning hair. Finasteride, sold under the brand name Propecia, is a 5-alpha reductase inhibitor approved by the FDA to treat male pattern hair loss at a dose of 1mg per day.

Originally developed by Merck, it became one of the most widely prescribed hair loss treatments in the world. For many men, the drug works as advertised. But a growing body of evidence, regulatory action, and patient testimony suggests that the psychiatric risks of finasteride have been systematically underplayed. The FDA did not add suicidal ideation and behavior to finasteride’s adverse reactions label until August 2022, more than two decades after the drug’s approval. And even then, the Patient Package Insert — the document most patients actually read — was not updated. This article traces the psychiatric risks tied to finasteride, from the clinical data to the regulatory failures, the legal aftermath, and what men considering the drug should actually know before filling that prescription. It is written not as a scare piece, but as an accounting of what the evidence says and what the system failed to communicate.

What Are the Side Effects of Finasteride That Men Never Hear About?
How Depression and Suicidality Became Finasteride’s Hidden Crisis
The Regulatory Timeline — Why Warnings Came Decades Late
What Men Should Ask Their Doctor Before Taking Finasteride
Post-Finasteride Syndrome and the Limits of Current Research
The Legal Fallout and What It Revealed
Where the Science and Policy Go From Here
Conclusion

What Are the Side Effects of Finasteride That Men Never Hear About?

Most men who ask their doctor about finasteride hear a version of the same reassurance: some patients experience sexual side effects, but they tend to resolve after stopping the medication. That framing is incomplete. According to FDA adverse event reports analyzed in a PLOS ONE pharmacovigilance study published in March 2025, the most commonly reported issues include erectile dysfunction (3,377 reports), sexual dysfunction (2,160 reports), and ejaculatory dysfunction (652 reports). Those numbers are significant, but they are also the side effects that at least make it into the conversation. What rarely enters the conversation is the psychiatric dimension. A meta-analysis found that suicidal ideation risk was 21.2% among finasteride users, compared to 14.0% without the drug.

FDA adverse event reports of suicidality associated with finasteride doubled between 2015 and 2024. A CBC and Radio-Canada six-month investigation documented men reporting sexual, psychological, and physical side effects lasting months or years after stopping finasteride. These are not patients who were predisposed to depression or had psychiatric histories. Many were otherwise healthy young men who went to a dermatologist about their hairline and left with a prescription that altered their neurochemistry in ways they were never told to watch for. The comparison worth making is this: if a drug for a cosmetic concern carried a meaningful risk of persistent sexual dysfunction alone, that would warrant a thorough informed consent process. When that same drug also carries documented risks of depression, cognitive changes, and suicidal thinking, the standard fifteen-second side effect disclaimer during a doctor visit is not sufficient. And yet, for most of finasteride’s commercial life, that is exactly what patients received.

What Are the Side Effects of Finasteride That Men Never Hear About?

How Depression and Suicidality Became Finasteride’s Hidden Crisis

The clinical data linking finasteride to depression is not ambiguous. In one study, researchers compared 61 former finasteride users who had developed persistent sexual side effects with 29 age-matched controls. Among the finasteride group, 64% had moderate-to-severe depression, compared to 0% of controls. that is not a marginal difference. It is a categorical one. The same study found depressive symptoms of any severity in 75% of the finasteride group. These findings, published in peer-reviewed literature, were available years before regulators acted on them. The suicidality data follows a similar pattern.

A research team at Hebrew University of Jerusalem published an article titled “Why Are We Still Ignoring the Suicide Risk of a Hair-Loss Drug?” — a question that remains largely unanswered by the medical establishment. The European Medicines Agency identified 313 cases of suicidal ideation for finasteride in its EudraVigilance database, drawn from an estimated 270 million patient-years of exposure. Critics point to that denominator to argue the absolute risk is small. However, if the reporting captures only a fraction of actual cases — as pharmacovigilance experts widely acknowledge — the true incidence could be substantially higher. Self-reporting bias works in both directions: many men experiencing depression after stopping a hair loss pill may never connect the two, and many who do may never file a formal adverse event report. There is also a temporal problem that complicates detection. Depression and suicidal ideation can emerge during treatment or after discontinuation, sometimes weeks or months later. A man who stops taking finasteride and develops depression three months afterward is unlikely to walk into his doctor’s office and say, “I think the hair loss drug I stopped taking is causing this.” The causal chain is not intuitive to patients, and unless a clinician is specifically watching for it, the connection goes unmade.

The Regulatory Timeline — Why Warnings Came Decades Late

The regulatory history of finasteride’s psychiatric warnings reads like a case study in institutional delay. The FDA first recognized depression as a possible side effect of finasteride in 2011, roughly fourteen years after the drug was approved for hair loss. For another eleven years, suicidal ideation remained absent from the label entirely. It was not until August 2022 that the FDA added suicidal ideation and behavior to finasteride’s adverse reactions section. But the agency made a decision that undercut its own action: the Patient Package Insert was not updated. The PPI is the document that pharmacies hand to patients with their prescription. It is, for most people, the only safety information they will ever read about a drug.

Leaving it unchanged meant that the warning existed in regulatory filings but not in the hands of the men taking the medication. Europe moved on a parallel but slightly different track. In October 2024, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee launched a comprehensive review of all finasteride-containing products. By 2025, the EMA confirmed that finasteride can cause suicidal ideation and urged healthcare professionals to advise patients to stop treatment immediately if they experience depressed mood or suicidal thoughts. That directive is more explicit than anything the FDA has issued to date. Then, in April 2025, the FDA issued a separate warning regarding compounded topical finasteride, noting 32 adverse event cases between 2019 and 2024 in which consumers reported they were not properly informed about risks or were told that topical application carried no side effects. This matters because compounded topical finasteride has become increasingly popular through telehealth platforms and direct-to-consumer hair loss companies, many of which market their products with a breezy tone that is fundamentally at odds with the drug’s risk profile. A man ordering finasteride through an app on his phone is even less likely to receive adequate informed consent than one sitting in a dermatologist’s office.

The Regulatory Timeline — Why Warnings Came Decades Late

What Men Should Ask Their Doctor Before Taking Finasteride

The practical question for any man considering finasteride is not whether the drug works — for many, it does — but whether the risk-benefit calculation has been honestly presented. A cosmetic treatment operates under a different ethical standard than a drug prescribed for a life-threatening illness. When someone takes chemotherapy, they accept severe side effects because the alternative is worse. When someone takes a pill to keep their hair, the calculus should involve a much lower tolerance for serious adverse events. Before filling a prescription, men should ask their prescribing physician several direct questions. Has the doctor read the updated FDA adverse reactions label, including the 2022 addition of suicidal ideation? What is their protocol if a patient develops depressive symptoms during or after treatment? Are they aware of post-finasteride syndrome, and do they have a plan for monitoring psychiatric health during treatment? If the physician dismisses these questions or is unfamiliar with the updated labeling, that is itself useful information. It does not necessarily mean the drug is wrong for every patient, but it does mean that particular provider is not equipped to manage its risks.

The tradeoff men face is real. Finasteride is one of only two FDA-approved oral treatments for androgenetic alopecia, and for many users, it is effective at slowing or reversing hair loss. The alternative — minoxidil — works through a different mechanism and carries its own limitations. Some men may decide that finasteride’s benefits justify its risks after a fully informed assessment. Others may decide the opposite. The problem has never been that finasteride exists. The problem is that for over two decades, the people prescribing it did not give patients the information needed to make that decision honestly.

Post-Finasteride Syndrome and the Limits of Current Research

Post-finasteride syndrome, or PFS, refers to persistent sexual, neurological, and psychological symptoms that continue after a patient stops taking the drug. It is perhaps the most contentious aspect of the finasteride debate. Some clinicians and researchers argue that PFS is a well-documented clinical entity supported by patient reports and emerging mechanistic research. Others contend that the evidence base is insufficient, pointing to self-reporting bias, the lack of standardized diagnostic definitions, and the absence of large-scale epidemiological studies. Both positions contain truth, and that ambiguity is itself the problem. The research that does exist — including the depression and suicidality studies cited above — is consistent enough to have moved two major regulatory agencies to action.

But it is not yet comprehensive enough to establish precise prevalence rates or to identify which patients are most at risk. There are no validated biomarkers for PFS. There is no consensus treatment protocol. Men who develop persistent symptoms after stopping finasteride often find themselves in a medical no-man’s land, shuttled between specialists who may not take the condition seriously or who lack the tools to treat it effectively. The limitation that matters most for patients is this: current science cannot reliably predict who will develop PFS and who will not. There is no genetic test, no screening questionnaire, no pre-treatment workup that will identify the men who will take finasteride without incident versus those who will spend years dealing with its aftermath. Until that changes, every prescription is to some degree a gamble, and patients deserve to know the stakes before they place the bet.

Post-Finasteride Syndrome and the Limits of Current Research

The Legal Fallout and What It Revealed

Roughly 1,400 lawsuits were filed against Merck in a federal multidistrict litigation designated MDL No. 2331, alleging that the company failed to adequately warn patients and physicians about finasteride’s sexual and psychological side effects. In April 2018, Merck settled 562 of those Propecia lawsuits for $4.3 million — a figure that works out to roughly $7,600 per plaintiff. For a company of Merck’s size, the settlement was financially negligible. The MDL was closed in January 2023, and as of 2025, no major new litigation campaigns appear to be active.

Most law firms are no longer accepting new Propecia cases. The legal chapter is instructive less for its outcomes than for what the litigation process surfaced. Discovery in pharmaceutical lawsuits often reveals internal communications and decision-making timelines that never reach the public through other channels. The fact that the litigation ultimately resolved for a modest sum does not mean the underlying claims lacked merit. It means that the legal system, like the regulatory system, moved slowly and settled cheaply relative to the harm alleged.

Where the Science and Policy Go From Here

The next several years will likely determine whether finasteride’s psychiatric risks are treated as a settled regulatory matter or as the beginning of a broader reckoning with how cosmetic pharmaceuticals are monitored after approval. The EMA’s 2025 directive represents the most aggressive regulatory stance to date, explicitly linking finasteride to suicidal ideation and mandating that healthcare professionals counsel patients on the risk. Whether the FDA follows with comparable patient-facing communication — particularly an update to the Patient Package Insert — remains an open question.

On the research front, the field needs prospective studies that follow finasteride users over time with standardized psychiatric assessments, rather than relying primarily on retrospective reports and adverse event databases. Identifying biological markers that predict susceptibility to PFS would transform the clinical conversation. Until then, the burden of due diligence falls on individual patients and the physicians who prescribe to them. For a drug taken by millions of men worldwide, that is an uncomfortable place for the burden to rest — but it is where the evidence currently leaves us.

Conclusion

Finasteride works for hair loss. That has never been in serious dispute. What has been in dispute — and what the evidence increasingly resolves against the drug’s proponents — is whether the psychiatric risks were adequately studied, disclosed, and communicated. The data shows elevated rates of depression, suicidal ideation, and persistent post-discontinuation symptoms that regulators took more than twenty years to formally acknowledge.

The FDA’s decision to update the adverse reactions label in 2022 while leaving the Patient Package Insert unchanged captures the problem in miniature: the information exists, but it does not reach the people who need it. For men considering finasteride or currently taking it, the most important step is a genuinely informed conversation with a knowledgeable physician — one that includes the psychiatric risks alongside the sexual ones, the possibility of persistent symptoms after stopping, and a monitoring plan for mood changes during treatment. Hair loss is a legitimate concern that affects self-image and quality of life. But the treatment should never carry risks that the patient was not given the chance to weigh. If you or someone you know is experiencing depression or suicidal thoughts, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.